RPPH1 Identified as Driver of High-Risk Acute Myeloid Leukemia Through NF-κB Activation and Th17 Cell Influence

Researchers have identified RPPH1 as a key driver in the progression of high-risk acute myeloid leukemia (AML), according to a recent study. The findings highlight the role of RPPH1 in activating NF-κB signaling pathways and influencing Th17 cells, providing new insights into the molecular mechanisms behind this aggressive form of cancer.

The study outlines how RPPH1 contributes to AML progression by interacting with NF-κB, a protein complex involved in regulating immune responses and inflammation. Additionally, researchers observed that RPPH1 impacts Th17 cells, which play a role in autoimmune diseases and inflammatory processes. These discoveries shed light on the biological pathways that enable high-risk AML to develop and progress, offering potential avenues for further research into targeted therapies.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

Cardinal Health VP Highlights Need for Long-Term Outcome Tracking to Justify Advanced Therapy Costs and Payment Models Analysis Calls for Expanded Clinical Roles to Help Pharmacists Reduce Medication Errors Inflammation and Metabolism Identified as Key Drivers in Heart Failure Progression Study Links Very Preterm Birth Before 32 Weeks to Higher Risks of Chronic Kidney Disease and Intellectual Disabilities

Author

GOAI